Pascal Furet

13.4k total citations · 1 hit paper
125 papers, 8.6k citations indexed

About

Pascal Furet is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Pascal Furet has authored 125 papers receiving a total of 8.6k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Molecular Biology, 50 papers in Oncology and 35 papers in Organic Chemistry. Recurrent topics in Pascal Furet's work include PI3K/AKT/mTOR signaling in cancer (24 papers), Cancer-related Molecular Pathways (22 papers) and Chronic Myeloid Leukemia Treatments (19 papers). Pascal Furet is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (24 papers), Cancer-related Molecular Pathways (22 papers) and Chronic Myeloid Leukemia Treatments (19 papers). Pascal Furet collaborates with scholars based in Switzerland, United States and United Kingdom. Pascal Furet's co-authors include Doriano Fabbro, Thomas Meyer, Patrick Chêne, Joseph Schoepfer, Carlos Garcı́a-Echeverrı́a, Giorgio Caravatti, Paul W. Manley, Elisabeth Buchdunger, Helmut Mett and Peter Traxler and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Angewandte Chemie International Edition.

In The Last Decade

Pascal Furet

125 papers receiving 8.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

2008 954 citations Sauveur-Michel Maira, Frédéric Stauffer et al. Molecular Cancer Therapeutics profile →

Peers

Countries citing papers authored by Pascal Furet

Since Specialization

Citations

This map shows the geographic impact of Pascal Furet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pascal Furet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pascal Furet more than expected).

Fields of papers citing papers by Pascal Furet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pascal Furet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pascal Furet. The network helps show where Pascal Furet may publish in the future.

Co-authorship network of co-authors of Pascal Furet

This figure shows the co-authorship network connecting the top 25 collaborators of Pascal Furet. A scholar is included among the top collaborators of Pascal Furet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pascal Furet. Pascal Furet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Capmatinib (INC280) Is Active Against Models of Non–Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation 2019 ·Clinical Cancer Research ·Sabrina Baltschukat, Barbara Schacher Engstler, Alan Huang, Huai-Xiang Hao, Angela Tam, Hui Qin Wang, Jinsheng Liang, Matthew T. DiMare, Hyo-Eun Carrie Bhang, Youzhen Wang, Pascal Furet, William R. Sellers, Francesco Hofmann, Joseph Schoepfer, Ralph Tiedt	105
2	Molecular and structural characterization of a TEAD mutation at the origin of Sveinsson's chorioretinal atrophy 2019 ·FEBS Journal ·Fedir Bokhovchuk, Yannick Mesrouze, (unknown), Marco Meyerhofer, Catherine Zimmermann, Patrizia Fontana, Tobias Schmelzle, Dirk Erdmann, Pascal Furet, Joerg Kallen, Patrick Chêne	21
3	Discovery of a novel tricyclic 4H-thiazolo[5′,4′:4,5]pyrano[2,3-c]pyridine-2-amino scaffold and its application in a PI3Kα inhibitor with high PI3K isoform selectivity and potent cellular activity 2015 ·Bioorganic & Medicinal Chemistry Letters ·Marc Gerspacher, Robin A. Fairhurst, Robert Mah, (unknown), Pascal Furet, Christine Fritsch, Daniel Guthy	20
4	The TEAD4–YAP/TAZ Protein–Protein Interaction: Expected Similarities and Unexpected Differences 2013 ·ChemBioChem ·(unknown), Dirk Erdmann, Yannick Mesrouze, Pascal Furet, Patrizia Fontana, Catherine Zimmermann, Tobias Schmelzle, Francesco Hofmann, Patrick Chêne	59
5	The central valine concept provides an entry in a new class of non peptide inhibitors of the p53–MDM2 interaction 2012 ·Bioorganic & Medicinal Chemistry Letters ·Pascal Furet, Patrick Chêne, Alain De Pover, Therese‐Marie Stachyra, Joanna Lisztwan, Joerg Kallen, Keiichi Masuya	52
6	A Drug Resistance Screen Using a Selective MET Inhibitor Reveals a Spectrum of Mutations That Partially Overlap with Activating Mutations Found in Cancer Patients 2011 ·Cancer Research ·Ralph Tiedt, (unknown), Pascal Furet, B.A. Appleton, (unknown), Joseph Schoepfer, Emily Buck, David A. Ruddy, John E. Monahan, Michael D. Jones, Jutta Blank, Dorothea Haasen, Peter Drueckes, Markus Wartmann, Clive McCarthy, William R. Sellers, Francesco Hofmann	99
7	Design of two new chemotypes for inhibiting the Janus kinase 2 by scaffold morphing 2010 ·Bioorganic & Medicinal Chemistry Letters ·Pascal Furet, Marc Gerspacher, Carole Pissot‐Soldermann	6
8	Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison 2010 ·Genes & Cancer ·(unknown), Johannes Roesel, Pascal Furet, Guido Bold, Patricia Imbach, Andreas Flörsheimer, Giorgio Caravatti, Jie Jiang, Paul W. Manley, Arghya Ray, James D. Griffin	33
9	New pyrazolo[1,5a]pyrimidines as orally active inhibitors of Lck 2010 ·Bioorganic & Medicinal Chemistry Letters ·Nina Gommermann, (unknown), (unknown), Werner Breitenstein, Keiichi Masuya, Bernard Pirard, Pascal Furet, Sandra W. Cowan‐Jacob, Gisbert Weckbecker	24
10	The Vascular Endothelial Growth Factor Receptor Inhibitor PTK787/ZK222584 Inhibits Aromatase 2009 ·Cancer Research ·Susana Banerjee, Marketa Zvelebil, Pascal Furet, (unknown), Dean B. Evans, Mitch Dowsett, Lesley‐Ann Martin	21
11	Extended kinase profile and properties of the protein kinase inhibitor nilotinib 2009 ·Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics ·Paul W. Manley, Peter Drueckes, Gabriele Fendrich, Pascal Furet, Janis Liebetanz, Georg Martiny‐Baron, Jürgen Mestan, Jörg Trappe, Markus Wartmann, Doriano Fabbro	179
12	Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity breakdown → 2008 ·Molecular Cancer Therapeutics ·Sauveur-Michel Maira, Frédéric Stauffer, Josef Brueggen, Pascal Furet, Christian Schnell, Christine Fritsch, Saskia M. Brachmann, Patrick Chêne, Alain De Pover, (unknown), Doriano Fabbro, Daniela Gabriel, Marjo Simonen, Leon O. Murphy, Peter M. Finan, William R. Sellers, Carlos García-Echeverría	954
13	Medicinal chemistry efforts towards the identification and development of inhibitors of phosphatidylinositol 3-kinases (PI3Ks) and related protein kinases for cancer treatment 2007 ·Cancer Research ·Frédéric Stauffer, Carlos Garcı́a-Echeverrı́a, Pascal Furet, Hans‐Georg Capraro, Philipp Holzer, Michel Maira	2
14	Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia 2006 ·Acta Crystallographica Section D Biological Crystallography ·Sandra W. Cowan‐Jacob, Gabriele Fendrich, Andreas Floersheimer, Pascal Furet, Janis Liebetanz, Gabriele Rummel, (unknown), (unknown), Doriano Fabbro, Paul W. Manley	215
15	Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases 2004 ·Bioorganic & Medicinal Chemistry Letters ·Paul W. Manley, Werner Breitenstein, Josef Brüggen, Sandra W. Cowan‐Jacob, Pascal Furet, Jürgen Mestan, Thomas Meyer	47
16	Imatinib: a selective tyrosine kinase inhibitor 2002 ·European Journal of Cancer ·Paul W. Manley, Sandra W. Cowan‐Jacob, Elisabeth Buchdunger, Doriano Fabbro, G. Fendrich, Pascal Furet, Thomas Meyer, J. Zimmermann	201
17	Modeling of the Binding Mode of a Non-covalent Inhibitor of the 20S Proteasome. Application to Structure-Based Analogue Design 2001 ·Bioorganic & Medicinal Chemistry Letters ·Pascal Furet, Patricia Imbach, Peter Fürst, Marc Lang, (unknown), Johann Zimmermann, Carlos Garcı́a-Echeverrı́a	26
18	2,6,9-trisubstituted purines : Optimization towards highly potent and selective CDK1 inhibitors 1999 ·Bioorganic & Medicinal Chemistry Letters ·Patricia Imbach, Hans‐Georg Capraro, Pascal Furet, Helmut Mett, Thomas Meyer, J. Zimmermann	74
19	Structural basis for the high affinity of amino-aromatic SH2 phosphopeptide ligands 1998 ·Journal of Molecular Biology ·Joseph Rahuel, Carlos Garcı́a-Echeverrı́a, Pascal Furet, André Strauss, Giorgio Caravatti, Heinz Fretz, Joseph Schoepfer, (unknown)	49
20	Different Susceptibility of Protein Kinases to Staurosporine Inhibition 1995 ·European Journal of Biochemistry ·Flavio Meggio, Arianna Donella Deana, Maria Ruzzene, Anna Maria Brunati, Luca Cesaro, Bárbara Guerra, Thomas Meyer, Helmut Mett, Doriano Fabbro, Pascal Furet, Grażyna Dobrowolska, Lorenzo A. Pinna	242

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact